Fluidigm Corporation announced the availability of the DELTAgene Assays (gene expression), SNPtype Assays (SNP genotyping), and Access Array Target-specific Primers (target enrichment for next-generation sequencing).
The ExactaCoat XYZ motion ultrasonic coating system from Sono-Tek Corporation is ideal for spraying medical device components such as pacemakers, diagnostic leads, or any small medical device requiring targeted coating of anti-microbials or other solutions.
arGEN-X announces that it has progressed ARGX-110, its second therapeutic candidate, into formal pre-clinical development. ARGX-110 has potential to improve treatment of autoimmune disorders, inflammation, and cancer.
Otsuka Pharmaceutical Co., Ltd. announced that a Phase 2 trial of OPC-34712, showed that patients demonstrated improvement in the Montgomery Åsberg Depression Rating Scale Total Score.
Perrigo Company announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter Ranitidine 150, a generic version of Zantac 150.
PerkinElmer, Inc. announced that it has acquired Labtronics Inc., an leader in providing procedures-based electronic laboratory notebook solutions for laboratories performing routine analysis in multiple industries.
Merck & Co. said it completed its $430 million purchase of eye-drug maker Inspire Pharmaceuticals Inc. In the deal, Merck gets Inspire's drug Azasite, which is used to treat pink eye caused by bacteria.
Mylan Inc. said it is now selling a generic version of Xibrom eye drops, which were discontinued in February by their original maker, ISTA Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd. said it will pay $460 million to acquire a majority stake in Japanese generic drugmaker Taiyo Pharmaceutical Industry Co., and said it expects its annual sales in Japan to reach $1 billion in the next few years.
Amylin Pharmaceuticals Inc. filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with Boehringer Ingelheim to develop and sell a competing product.
The Leukemia & Lymphoma Society (LLS) and Acetylon Pharmaceuticals announced a business alliance to jointly support a Phase I/II clinical trial of Acetylon’s HDAC6 inhibitor drug candidate, ACY-1215, in multiple myeloma.
BioFocus has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders.
Scientists from The Scripps Research Institute have identified a class of compounds that powerfully and selectively block the activity of a large and diverse group of enzymes known as serine hydrolases.. Previously discovered serine hydrolase-blocking compounds have been turned into drugs to treat obesity, diabetes, and Alzheimer’s disease, and are currently in testing as treatments for pain, anxiety, and depression.
Researchers at the University of Washington have demonstrated the use of computational methods to design new antiviral proteins capable of targeting specific surfaces of flu virus molecules.